Selected article for: "case control and randomised trial"
Author: Hill, T.; Baker, M.; Isherwood, L.; Lee, L. Y.
Title: Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
  • Cord-id: t2nuvh0n
  • Document date: 2020_8_14
    • ID: t2nuvh0n
    Snippet: Objectives: To identify putative COVID-19 treatments and identify the roles of immunomodulators and antivirals in disease management. Design: Systematic review. Data sources: PubMed, bioRxiv.org and medRxiv.org were searched for studies suggestive of effective treatments for COVID-19. Additional studies were identified via a snowballing method applied to the references of retrieved papers as well as a subsequent targeted search for drug names. Review methods: Inclusion criteria included any case
    Document: Objectives: To identify putative COVID-19 treatments and identify the roles of immunomodulators and antivirals in disease management. Design: Systematic review. Data sources: PubMed, bioRxiv.org and medRxiv.org were searched for studies suggestive of effective treatments for COVID-19. Additional studies were identified via a snowballing method applied to the references of retrieved papers as well as a subsequent targeted search for drug names. Review methods: Inclusion criteria included any case series or randomised control trials in any language that were published from 18th December 2019 to 18th April 2020 and described COVID-19 treatment. Of an initial 2140 studies identified from the initial search, 29 studies were found to meet the inclusion criteria and included in this comprehensive systematic review. Results: 19 studies of antiviral treatments for COVID-19 have been reported and seven studies for immunomodulatory treatments. Six randomised controlled trials have been published with one positive trial for Hydroxychloroquine. This small study consisted of 31 patients though subsequent studies showed contradictory findings. All the remaining studies were observational studies, retrospective case reviews or non-randomised trials and these results are difficult to interpret due to methodological issues. Conclusions: To date, an impressive number of studies have been performed in a short space of time, indicative of a resilient clinical trials infrastructure. However, there is a lack of high quality evidence to support any novel treatments for COVID-19 to be incorporated into the current standard of care. The majority of the studies of treatments for COVID-19 could only be found in pre-print servers. Future clinical reviews should therefore be Comprehensive Systematic Reviews involving pre-print studies to prevent potential unnecessary replications of clinical studies.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir perform: 1
    • acute respiratory syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte neutrophil include: 1
    • acute respiratory syndrome cause and lopinavir ritonavir: 1, 2, 3, 4
    • acute respiratory syndrome cause and low molecular weight heparin: 1, 2
    • acute respiratory syndrome cause and lymphocyte neutrophil: 1, 2
    • acute respiratory syndrome cause and lymphocyte neutrophil include: 1
    • adequate oxygenation and lymphocyte neutrophil: 1
    • lopinavir ritonavir and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • lopinavir ritonavir and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6
    • low molecular weight heparin and lymphocyte neutrophil: 1, 2, 3, 4